A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Irinotecan; Levofolinic acid
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 01 Nov 2019 Results assessing exploration of prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer published in the Cancer Science
- 01 Mar 2019 Results assessing assessing the efficacy, safety and pharmacokinetics published in the Cancer Science.
- 21 Jan 2017 Preliminary results assessing association between pharmacodynamic biomarkers and overall survival, presented at the 2017 Gastrointestinal Cancers Symposium